BioSpace News Archive

PathMaker Neurosystems Inc., a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with spasticity and paralysis announces the first publication of clinical trial results for its MyoRegulator® device for the non-invasive treatment of spasticity.

Nevro Corp. announced that U.S. District Judge Colm Connolly, in the District of Delaware, granted Nevro’s motion for preliminary injunction, and has issued an order barring Stimwave Technologies, Inc., and all affiliated persons and entities, from infringing patent claims covering frequencies between 3 kHz and 10 kHz by programming Stimwave’s SCS systems to deliver its recently introduced high-frequency, paresthesia-free SCS therapy.

Rapid Dose Therapeutics Corp. announced that they have completed the last phase of the Managed Strip Services Agreement signed in January 2019 with Flower One Holdings Inc., pursuant to which Flower One has been granted Gold Vendor Status to manufacture, distribute and sell RDT’s QuickStrip™, an innovative, proprietary delivery technology, for the cannabis market in Nevada, USA.

ADVANZ PHARMA Corp. commented on the issuance by the UK Competition and Markets Authority of a Statement of Objections to various parties, including ADVANZ PHARMA, related to competition matters pertaining to the Company’s medicines, nitrofurantoin capsules 50mg and 100mg.

NDA Seeks Approval for Brinavess for the Treatment of Recent Onset Atrial Fibrillation; PDUFA Date Set for December 24, 2019

Verastem, Inc. announced that the Company will host a conference call and webcast on Thursday, August 1, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2019.

Massachusetts General Hospital and ElevateBio, a cell and gene therapy holding company, announced that they have entered into a 10-year alliance agreement.

Covalon Technologies Ltd., an advanced medical technologies company, wishes to provide the following corporate update

Anticipates $500 million investment to support Advancing American Kidney Health Initiative

HOUSTON, July 25, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has identified a third site as well as the supervising physician for its upcoming expanded pivotal Cellulite Trial.